EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application febuxostat tablets, 40mg and 80mg. Aurobindo Pharma’s febuxostat tablets, are an AB-rated generic equivalent to the reference listed drug (RLD), Uloric Tablets, manufactured by Takeda Pharmaceuticals U.S.A., Inc.
Febuxostat tablets are indicated for the chronic management of hyperuricemia in patients with gout.
Topiramate capsules has an estimated market size of US $28 Million for the twelve months ending August 2023, as per IQVIA.
